Glaucoma Pipeline Drugs: Targeting the Trabecular Meshwork
Finding drugs that affect outflow through the trabecular meshwork—without intolerable side effects—has long been an elusive goal. Are we getting closer to bringing new classes of drugs to market?
Experts who follow drug development are hopeful that we're on the brink of reaping the benefits of years of research.
EyeNet introduces its brand new mobile-optimized digital edition—all the benefits of the print edition, plus digital enhancements.
Read on a break at work, kicking back at home with your iPad, or on your phone while in line at the grocery store. Check it out.